Cognition Therapeutics Study Of Zervimesine (CT1812) In Early Alzheimer’s Disease Surpasses 50% Enrollment Target
July 1 (Reuters) - Cognition Therapeutics Inc CGTX.O:
COGNITION THERAPEUTICS STUDY OF ZERVIMESINE (CT1812) IN EARLY ALZHEIMER’S DISEASE SURPASSES 50% ENROLLMENT TARGET
COGNITION THERAPEUTICS STUDY OF ZERVIMESINE (CT1812) IN EARLY ALZHEIMER’S DISEASE SURPASSES 50% ENROLLMENT TARGET
COGNITION THERAPEUTICS INC - PHASE 2 SHINE STUDY SHOWS 38% SLOWING OF COGNITIVE DECLINE WITH ZERVIMESINE
COGNITION THERAPEUTICS INC - LOWER P-TAU217 LEVELS SHOW 95% SLOWING OF COGNITIVE DECLINE WITH ZERVIMESINE
COGNITION THERAPEUTICS INC - START STUDY RECEIVES $81 MILLION GRANT SUPPORT FROM NIA
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Vanguard ETF Could Beat the S&P 500 Again in 2026 —— Why Investors Are Paying Attention

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Big Tech’s AI Data Center Power Demands Trigger $15B PJM Auction and a Nuclear SMR Boom

Tradingkey








